announced the reintroduction of the PrEP Assistance Program Act to make the preventative HIV drug PrEP more affordable and accessible to underserved and high-risk populations
Make PrEP more affordable and accessible to underserved and high-risk populations.
Occurrences
Evidence
The official newsroom's latest visible items are dated June 3, May 29, and May 28, 2026 and cover House passage of a resolution on Iran, a worker-rights bill, and ICE abuses at Delaney Hall; the feed does not show a PrEP- or HIV-specific post in this window.
Watson Coleman's official legislation page lists H.R.5127 as cosponsored: a bill requiring no-cost coverage of certain HIV prevention services; it also lists H.R.5126 as cosponsored for CDC HIV prevention funding.
Congress.gov lists H.R.5127 as introduced on 09/04/2025, referred to House committees, and still at the Introduced step rather than passed or enacted.
The H.R.5127 cosponsors page lists Rep. Watson Coleman, Bonnie [D-NJ-12] with an asterisk as an original cosponsor dated 09/04/2025.
The bill text would require no-cost coverage for FDA-approved HIV prevention drugs, including PrEP and PEP, related lab work, counseling, follow-up, and monitoring across private coverage, Medicare, Medicaid, and CHIP.
Congress.gov lists H.R.5126 as introduced on 09/04/2025, referred to the House Committee on Appropriations, and still at the Introduced step.
The H.R.5126 cosponsors page lists Rep. Watson Coleman, Bonnie [D-NJ-12] with an asterisk as an original cosponsor dated 09/04/2025.
The bill would appropriate $2.165 billion for FY2026 programs and activities of CDC's National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention.
Assessments
The record provided does not show that Bonnie Watson Coleman delivered the promised outcome or materially advanced a specific federal PrEP affordability/access measure. The only evidence is the absence of a PrEP- or HIV-specific item in her recent official news feed, which is not enough to prove either fulfillment or failure. With no cited bill sponsorship, enacted policy change, appropriations win, or executive action tied to her, the safest judgment is unresolved.